Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totalling 372,500 shares, a decrease of 6.0% from the July 15th total of 396,200 shares. Based on an average daily volume of 22,200 shares, the days-to-cover ratio is currently 16.8 days. Currently, 6.5% of the company’s stock are short sold.

Institutional Trading of Aytu BioPharma

An institutional investor recently raised its position in Aytu BioPharma stock. Dimensional Fund Advisors LP grew its position in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 54.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,551 shares of the company’s stock after purchasing an additional 8,311 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.39% of Aytu BioPharma worth $69,000 at the end of the most recent reporting period. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

Aytu BioPharma Stock Up 1.5 %

Aytu BioPharma stock opened at $2.64 on Monday. Aytu BioPharma has a 52-week low of $1.52 and a 52-week high of $3.50. The firm has a market cap of $15.77 million, a PE ratio of -1.00 and a beta of -1.41. The company’s 50 day moving average is $2.75 and its two-hundred day moving average is $2.92.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.